Core Insights - BioStem Technologies, Inc. has filed restated interim financial statements for Q1 2024 through Q2 2025 and annual financial statements for 2023 and 2024, aligning with US GAAP revenue recognition standards [3][12]. Financial Restatement - The restatement is a significant milestone for the company, resulting from a comprehensive review of US GAAP revenue recognition guidance, particularly regarding the distribution agreement with Venture Medical [4][12]. - Bona fide services fees previously recorded as Sales and Marketing expenses will now be classified as contra revenue, reducing gross revenue but not impacting EBITDA, net income, or cash flow [5][12]. - The restated financials will affect percentage-based metrics such as gross margin and EBITDA margin due to the change in revenue reporting [5]. Balance Sheet Adjustments - Amounts owed to Venture Medical related to bona fide services fees will now be netted against Accounts Receivable, effectively offsetting the liabilities between the two companies [6]. Business Outlook - The company maintains that the underlying strength of its business remains unchanged, continuing to deliver clinically validated wound care products [7]. - The independent audit led by KPMG is expected to be completed by the end of Q1 2026, which will support the company's plans to uplist and enhance investor transparency [8][12].

Company Overview - BioStem Technologies, Inc. is a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care [5] - The company utilizes its proprietary BioREtain processing method to maintain growth factors and preserve tissue structure in its allografts [5] Market Position and Opportunities - Jason Matuszewski, Chairman and CEO, will present BioStem's current position in the chronic wound care market and key opportunities for growth at the Advanced Wound Care Summit on July 15, 2025 [1] - The company aims to drive continued growth in its core allograft business while pursuing opportunities to expand its portfolio across the continuum of care [8] Event Details - The Advanced Wound Care Summit will take place from July 15 to 17, 2025, bringing together global leaders in wound care innovation and clinical research [3] - The summit will feature keynote presentations, interactive panels, and strategic networking opportunities to address unmet needs in chronic wound management [3] Quality and Compliance - BioStem's quality management systems and standard operating procedures are accredited by the American Association of Tissue Banks (AATB) and adhere to Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [6] - The company's products are processed at an FDA registered and AATB accredited site in Pompano Beach, Florida [6]

Core Viewpoint - BioStem Technologies, Inc. is progressing towards uplisting to the Nasdaq Capital Market following the anticipated approval of its amended Form 10 by the SEC, which includes audited financial statements for fiscal years 2023 and 2024, and unaudited results for Q1 2025 [2][4]. Group 1: SEC Review Process - BioStem has resolved outstanding SEC accounting comments and plans to file an amended Form 10 by the end of June 2025 [2]. - The company initially submitted its Form 10 in September 2024 and has been collaborating with auditors and the SEC to address accounting treatment questions related to revenue and service fees [3]. - The uplisting is contingent upon the effectiveness of the Form 10 and meeting other Nasdaq listing requirements [3]. Group 2: Company Overview - BioStem is a MedTech company focused on developing, manufacturing, and commercializing placental-derived products for advanced wound care, utilizing its proprietary BioREtain® processing method [6]. - The company’s quality management systems are accredited by the American Association of Tissue Banks and adhere to Good Tissue Practices and Good Manufacturing Processes [7]. Group 3: Leadership and Communication - Jason Matuszewski, BioStem's CEO, expressed optimism about the progress made in the SEC review process and thanked the team for their commitment [4]. - The company encourages stakeholders to stay informed through its distribution list and social media channels [5].